UB Paderborn / Katalog / Suche / in CDI

1 – 19 von 19

Sortiert nach

FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC

Clinical cancer research, 2022-04, Vol.28 (8), p.1482-1486

2022

Volltextzugriff (PDF)

Metabolic symbiosis in cancer: Refocusing the Warburg lens

Molecular carcinogenesis, 2013-05, Vol.52 (5), p.329-337

2013

Volltextzugriff (PDF)

Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event

Journal of clinical oncology, 2019-10, Vol.37 (30), p.2714-2718

2019

Volltextzugriff (PDF)

Quantifying metabolic heterogeneity in head and neck tumors in real time: 2-DG uptake is highest in hypoxic tumor regions

PloS one, 2014-08, Vol.9 (8), p.e102452

2014

Volltextzugriff (PDF)

Assessing the inter-observer variability of Computer-Aided Nodule Assessment and Risk Yield (CANARY) to characterize lung adenocarcinomas

PloS one, 2018-06, Vol.13 (6), p.e0198118-e0198118

2018

Volltextzugriff (PDF)

FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma

Clinical cancer research, 2022-02, Vol.28 (3), p.446-451

2022

Volltextzugriff (PDF)

Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group

JCO precision oncology, 2024-04, Vol.8, p.e2300687

2024

Volltextzugriff (PDF)

Innovation in recruitment and curricular design for diversity, equity, and inclusion (DEI) education for hematology-oncology (HO) trainees

Journal of clinical oncology, 2022-10, Vol.40 (28_suppl), p.179-179

2022

Volltextzugriff (PDF)

Hematology/medical oncology fellow responses to the initial development of an antiracism curriculum

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.11042-11042

2021

Volltextzugriff (PDF)

Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9000-9000

2022

Volltextzugriff (PDF)

Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9001-9001

2022

Volltextzugriff (PDF)

Reflection rounds to facilitate resilience in hematology/medical oncology fellows

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.11019-11019

2020

Volltextzugriff (PDF)

CT and PET radiomic features associated with major pathologic response to neoadjuvant immunotherapy in early-stage non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9031-9031

2020

Volltextzugriff (PDF)

Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event

Journal of clinical oncology, 2019-08, p.JCO1901623

2019

Volltextzugriff (PDF)

Trial in progress: Neoadjuvant immune checkpoint blockade in resectable malignant pleural mesothelioma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS9078-TPS9078

2020

Volltextzugriff (PDF)

Assessing the inter-observer variability of Computer-Aided Nodule Assessment and Risk Yield

PloS one, 2018-06, Vol.13 (6), p.e0198118

2018

Volltextzugriff (PDF)

Abstract 3723: Assessing the reproducibility of computer-aided nodule assessment and risk yield (CANARY) method to characterize lung adenocarcinomas

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3723-3723

2017

Volltextzugriff (PDF)

1 – 19 von 19

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(19)

Sprache

Englisch
(19)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(17)
NUS Single-Journal Subscriptions
(14)
Ovid SocietyJournals and Single Titles
(11)
Ingenta
(8)
IngentaConnect Journals
(7)
MEDLINE
(6)
Springer journals
(2)
Wiley-Blackwell Journals
(1)
Wiley Online Library
(1)

4 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC

Metabolic symbiosis in cancer: Refocusing the Warburg lens

Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event

Quantifying metabolic heterogeneity in head and neck tumors in real time: 2-DG uptake is highest in hypoxic tumor regions

Assessing the inter-observer variability of Computer-Aided Nodule Assessment and Risk Yield (CANARY) to characterize lung adenocarcinomas

FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma

Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group

Innovation in recruitment and curricular design for diversity, equity, and inclusion (DEI) education for hematology-oncology (HO) trainees

Hematology/medical oncology fellow responses to the initial development of an antiracism curriculum

Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis

Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis

Reflection rounds to facilitate resilience in hematology/medical oncology fellows

CT and PET radiomic features associated with major pathologic response to neoadjuvant immunotherapy in early-stage non-small cell lung cancer (NSCLC)

Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event

Trial in progress: Neoadjuvant immune checkpoint blockade in resectable malignant pleural mesothelioma

Assessing the inter-observer variability of Computer-Aided Nodule Assessment and Risk Yield

Abstract 3723: Assessing the reproducibility of computer-aided nodule assessment and risk yield (CANARY) method to characterize lung adenocarcinomas

JADES: Possible Population III signatures at z = 10.6 in the halo of GN-z11

JADES

Suchergebnisse filtern